Calzada-León Raúl
Servicio de Endocrinología, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México, México.
Rev Med Inst Mex Seguro Soc. 2017 Mar-Apr;55(2):196-213.
Recombinant human growth hormone, synthesized in E.coli or mammalian cells cultures, is since 1985, a useful therapeutic resource to increase growth velocity and final height. In this paper are discussed the four phases (aims, security and efficacy, utility and efficiency) indispensables to define the start of treatment, as well as the absolute, relative and metabolic indications and the transitory and permanent conditions that contraindicate its use. It is commented the way to optimize the results (simple but indispensables indications for the physician, the patients and their family). Finally it is analyzed the results of treatment in patients with growth hormone deficiency, Turner syndrome, chronic renal failure, Prader-Willi syndrome, Noonan syndrome, SHOX deficiency, intrauterine growth retardation and idiopathic short stature.
重组人生长激素,于1985年开始在大肠杆菌或哺乳动物细胞培养物中合成,是一种用于提高生长速度和最终身高的有效治疗资源。本文讨论了确定治疗开始所必需的四个阶段(目标、安全性和有效性、实用性和效率),以及绝对、相对和代谢适应症,以及禁忌使用的暂时和永久情况。文中还阐述了优化治疗效果的方法(对医生、患者及其家属而言简单但必不可少的适应症)。最后分析了生长激素缺乏症、特纳综合征、慢性肾功能衰竭、普拉德-威利综合征、努南综合征、SHOX缺乏症、宫内生长迟缓及特发性身材矮小患者的治疗结果。